Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.40 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605247 | 0.93 | MAOB (0.53) | GPR132CYP19A1MAOBPTPN1NR4A2 | |
| SCHEMBL5604731 | 0.90 | MAOB (0.56) | GPR132CYP19A1MAOBPTPN1NR4A2 | |
| SCHEMBL5604633 | 0.90 | SMPD1 (0.53) | MAOBPTPN1NR4A2MAOASLC2A1 | |
| SCHEMBL5747022 | 0.89 | GPR132 (0.52) | GPR132 | |
| SCHEMBL5604369 | 0.88 | SMPD1 (0.53) | CYP19A1MAOBPTPN1NR4A2MAOA | |
| SCHEMBL5746431 | 0.85 | GPR132 (0.46) | GPR132MAOBPTPN1NR4A2 | |
| SCHEMBL5604816 | 0.84 | NPC1 (0.38) | — | |
| SCHEMBL5605266 | 0.82 | ALDH1A1 (0.44) | — | |
| SCHEMBL5605781 | 0.81 | ALDH1A1 (0.41) | — | |
| SCHEMBL5605161 | 0.79 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144889-B2 | Triarylimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1675848-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005040153-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085473-A1 | Novel triarylimidazoles | HOFFMANN-LA ROCHE INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085473-A1 | Novel triarylimidazoles | AURKAIP1, GLS2, GOT2 | GPR132 1076/4885CYP19A1 241/4885MAOB 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.